ImmuPharma (GB:IMM) has released an update.
ImmuPharma PLC, the specialist drug discovery and development company, has successfully sold its entire stake of approximately 9.9 million shares in Incanthera plc, generating gross proceeds of around £1.5 million. Despite this sale, ImmuPharma still holds about 7.3 million warrants in Incanthera, exercisable until 6 September 2024. ImmuPharma is known for developing peptide-based therapeutics, focusing on treatments for autoimmune diseases and anti-infectives, with its leading program P140 targeting Lupus and CIDP.
For further insights into GB:IMM stock, check out TipRanks’ Stock Analysis page.
